Is Editas Medicine a Buy?

Is Editas Medicine a Buy?

Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Meanwhile, the industry indicator, iShares NASDAQ Biotechnology Index (NASDAQ: IBB), only returned a total of 41%. The most mind-boggling aspect of Editas is that the company already has a staggering $4.1 billion market cap -- despite having no therapies out on the market.